SuperworthDow DOW
- Market cap
- $23.6B
- PE
- n/m
- a loss over the last year
- Forward PE
- 16.9×
- 8y median 20.2×
- Price to sales
- 0.6×
- EV/EBIT
- 16.1×
- Revenue, 12 months
- $41.3B
- −1% on a year ago
- Net margin
- −3.1%
- Free cash flow yield
- 6.8%
Dow trades at 0.6× sales. Its trailing earnings are negative, so it has no PE. Revenue was $41.3B over the last twelve months, down 1% on a year earlier with a −3% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $10.7B−24% | $10.6B−10% | $10.8B−9% | $10.9B−4% | $10.9B+1% | $10.4B−2% | $10.4B−3% | $10.1B−7% | $10B−8% | $9.5B−9% | $9.8B−6% | $12.1B+20% | |
| Cost of revenue | $9.6B−23% | $9.6B−10% | $9.5B−11% | $9.6B−3% | $9.8B+2% | $9.5B−2% | $9.8B+3% | $9.5B−1% | $9.2B−6% | $8.9B−6% | $9.2B−6% | $9.9B+4% |
| Gross profit | $1.1B−34% | $975M−19% | $1.3B+5% | $1.3B−14% | $1.1B−6% | $935M−4% | $671M−48% | $583M−56% | $731M−32% | $548M−41% | $640M−5% | $2.2B+272% |
| R&D | $197M+3% | $213M−5% | $204M−5% | $196M−4% | $208M+6% | $202M−5% | $200M−2% | $188M−4% | $191M−8% | $173M−14% | $181M−10% | $207M+10% |
| SG&A | $380M+7% | $411M+7% | $442M+3% | $390M−4% | $396M+4% | $353M−14% | $366M−17% | $347M−11% | $340M−14% | $339M−4% | $417M+14% | $535M+54% |
| $480M−57% | $291M−50% | $505M | $661M−22% | $366M−24% | $270M−7% | −$179M | −$606M | $131M−64% | −$1B | −$31M−83% | $882M | |
| Interest expense | $192M+24% | $197M+13% | $199M+8% | $197M+15% | $199M+4% | $216M+10% | $216M+9% | $209M+6% | $221M+11% | $219M+1% | $219M+1% | $210M+1% |
| Pre-tax income | $417M−58% | −$352M | $449M | $608M−15% | $324M−22% | $219M | −$374M | −$659M | $70M−78% | −$1.5B | −$390M+4% | $871M |
| $90M−63% | −$257M | −$89M+89% | $150M−29% | $84M−7% | $254M | −$84M−6% | $142M−5% | −$54M | −$71M | $55M | $69M−51% | |
| Net income | $302M−59% | −$105M | $516M | $439M−10% | $214M−29% | −$53M−50% | −$307M | −$835M | $62M−71% | −$1.5B+2811% | −$533M+74% | $721M |
| $0.42−59% | −$0.14 | $0.73 | $0.62−9% | $0.30−29% | −$0.06−57% | −$0.44 | −$1.18 | $0.08−73% | −$2.14+3467% | −$0.74+68% | $0.99 | |
| 707.5M−2% | 703.6M−1% | 705.5M−0% | 705.3M−1% | 703.6M−1% | 704.7M+0% | 706.9M+0% | 709.5M+1% | 713.2M+1% | 718.1M+2% | 721.2M+2% | 725.1M+2% |
Gross profit: 34 periods, Q1 FY18 to Q2 FY26: not printed by the filing, worked out from its own lines.
Operating income: 29 periods, Q1 FY19 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 9 periods, Q1 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY18: share-days: the 6-month average less the second quarter's. 3 periods, Q4 FY18 to Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $11.2B | $11B to $11.6B | $0.64 | $0.58 to $0.70 | 10 |
| Q4 FY26 | $10.8B | $10B to $11.3B | $0.53 | $0.30 to $0.78 | 10 |
| Q1 FY27 | $10.6B | $10.4B to $10.8B | $0.44 | $0.31 to $0.56 | 5 |
| Q2 FY27 | $11.3B | $10.7B to $11.9B | $0.58 | $0.54 to $0.62 | 3 |
| Q3 FY27 | $11.2B | $10.5B to $11.8B | $0.54 | $0.50 to $0.58 | 3 |
| Q4 FY27 | $10.9B | $10.3B to $11.5B | $0.21 | $0.20 to $0.23 | 3 |
| Q1 FY28 | $11.1B | $10.5B to $11.7B | $0.35 | $0.32 to $0.37 | 4 |
| Q2 FY28 | $12B | $11.3B to $12.6B | $0.53 | $0.49 to $0.56 | 4 |
Peers
Companies in Chemicals nearest Dow's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DOWDow | $23.6B | n/m | 21.9× | 16.9× | 0.6× | −1% | −3.1% |
| DDDuPont de Nemours | $18.4B | 303× | 22.8× | n/m | 2.6× | +3% | 0.8% |
| ALBAlbemarle | $11.1B | 347× | 25.7× | n/m | 1.9× | +18% | 3.8% |
| ESIElement Solutions | $8.1B | 44.9× | 30.1× | n/m | 2.6× | +27% | 5.7% |
| EMNEastman Chemical | $7.4B | 16.9× | 13.4× | n/m | 0.8× | −5% | 5.0% |
| HXLHexcel | $6B | 40.0× | 35.9× | n/m | 3.0× | +5% | 7.8% |
| BCPCBalchem | $5.6B | 34.8× | 41.0× | n/m | 5.2× | +9% | 15.1% |
| CSWCSW Industrials | $4.8B | 40.6× | 34.7× | n/m | 4.1× | +28% | 10.3% |
| CBTCabot | $3.8B | 20.8× | 14.4× | n/m | 1.0× | −5% | 5.2% |
| AVNTAvient | $3.8B | 22.2× | 20.2× | n/m | 1.1× | +2% | 5.1% |
| WDFCWD 40 | $2.9B | 32.3× | 39.2× | n/m | 4.2× | +10% | 13.2% |
| Peer median | $5.8B | 37.4× | 27.9× | n/a | 2.6× | +7% | 5.4% |
More on Dow
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 22Materials stocks with the highest dividend yields
- #3of 17Materials stocks with the lowest PEG ratio
- #9of 21Materials stocks with the lowest forward PE
- #10of 23Chemicals stocks with the lowest EV/EBIT
Its groups
About
- Industry
- Chemicals
- Sector
- Basic Materials
Valuation data, not investment advice. Prices as of .